Answers are grounded in this paper and cite their sources.
Fabry disease (FD) is a lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient α-galactosidase A (α-GalA) activity and progressive accumulation of globotriaosylceramide (Gb3). Cardiac involvement is the leading cause of morbidity and mortality in FD, yet the cellular mechanisms driving FD cardiomyopathy remain incompletely understood. Human dermal fibroblasts from FD patients were reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into beating cardiomyocytes (CMs), which were evaluated for GLA expression, Gb3 accumulation, cardiac gene expression, protein abundance, intracellular Ca²⁺ handling, mitochondrial membrane potential, and mitophagy. FD-iPSC-CMs recapitulated key molecular features of FD, including reduced GLA expression and protein abundance together with intracellular Gb3 accumulation. Compared with control CMs, FD-iPSC-CMs exhibited altered expression of cardiac developmental, ion-channel, hypertrophic, and mitochondrial dynamics genes. FD-iPSC-CMs displayed a significantly decreased spontaneous beating rate, reduced mitochondrial membrane potential and impaired mitophagy, and disruption of cellular Ca²⁺ handling. Patient-derived iPSC-CMs reproduce key molecular and functional features of FD cardiomyopathy. These findings establish a human disease model for investigating the mechanisms of FD cardiomyopathy and for evaluating targeted therapeutic strategies. Not applicable.
No takes yet. Share an insight, caveat, or question.
Varzideh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: